The greater chemotherapy exposure among MSS patients in our dataset thus reflects standard-of-care treatment selection rather than inherent tumor aggressiveness, although survival outcomes for MSS patients remained poorer in this BRAF-mutant subgroup, highlighting the need for novel therapeutic approaches. Here, BRAF is linked to neoplasm.